A novel in-vivo chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) has shown encouraging results in treating patients with relapsed or refractory multiple myeloma (RRMM), a blood cancer that remains difficult to manage after initial treatment regimens fail.
Unlike conventional CAR T-cell therapies that require complex and costly ex vivo cell processing, this in-vivo method involves the direct delivery of gene-editing vectors into the patient’s body. These vectors reprogram the patient’s own T cells to target and kill multiple myeloma cells presenting the BCMA protein, a marker highly expressed on most myeloma cells.
Early clinical data indicate that this approach has the potential to reduce the logistical challenges associated with traditional CAR T-cell therapy, such as manufacturing delays and the need for specialized treatment centers. The in-vivo technique could significantly boost patient access, particularly in resource-limited settings.
Patients with RRMM often experience diminishing responses to standard treatments, leading to poor survival outcomes. BCMA has emerged as a validated target in such cases, and multiple CAR T-cell therapies targeting BCMA are either approved or in advanced clinical trials. However, the conventional production of personalized CAR T cells involves harvesting a patient’s T cells, genetically modifying and expanding them in specialized laboratories, and then reinfusing them—an expensive and time-consuming process that limits widespread availability.
The in-vivo strategy, now under clinical investigation, utilizes non-viral delivery methods or nanoparticle technologies to insert CAR genes directly into circulating T cells. This results in the generation of CAR T cells within the patient’s body, bypassing the need for external cell processing. Preliminary safety and efficacy outcomes are under evaluation, with researchers closely monitoring the immune response and potential toxicity associated with the novel technique.
This innovative approach to CAR T-cell therapy reflects a broader trend in oncology focused on enhancing treatment efficiency and accessibility. As research advances, in-vivo immunotherapy may become a transformative option for patients with hard-to-treat blood cancers such as multiple myeloma. Further studies are ongoing to confirm long-term outcomes, optimize delivery methods, and expand the scope of treatable malignancies.
Source: https:// – Courtesy of the original publisher.
